pointbiopharma(PNT) - 2023 Q2 - Quarterly Report

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ______to ______. Commission file number: 001-39311 POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (IRS Employer Identification No.) incorporation or organization) 4850 West 78th Street Indianapolis, IN 46268 (Address of ...